DOI: 10.1055/s-00000133

Gastroenterologie up2date

References

Zhu AX, Kang YK, Yen CJ. et al.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2019;
20: 282-296

Download Bibliographical Data

Access:
Access: